StockData
Cytokinetics Inc logo

Cytokinetics Inc (CYTK) shareholders

CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30
$51.65−1.52 (-2.86%)

Close on Nov 17, 2026Market cap $7.18BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
160M of 139M shares
Institutional holders
482
95 new, 47 sold out
Net institutional buying
14M
In Q2 2026
Insider trades, 12 months
0 buys · 86 sales
Net sold $51.99M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
T. Rowe Price Investment Management, Inc.17,716,37214.50%13G (passive) amendmentDec 31, 2025
BlackRock, Inc.15,252,90513.00%13G (passive) amendmentSep 30, 2024
FMR LLC
Joint filing with Abigail P. Johnson (9.00%)
11,135,1929.00%13G (passive) amendmentMar 31, 2026
State Street Corporation7,143,2295.10%13G (passive)Sep 30, 2026
Wellington Investment Advisors Holdings LLP
Joint filing with Wellington Management Group LLP (5.10%), Wellington Group Holdings LLP (5.10%)
7,116,7245.10%13G (passive) amendmentJun 30, 2026
Vanguard Capital Management6,422,0425.21%13G (passive)Mar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of CYTKValueChange% of portfolio
BlackRock, Inc.20,094,36214.45%$1.71B+3,546,3510.03%
T. Rowe Price Investment Management, Inc.18,718,49813.46%$1.59B+1,194,6581.05%
Wellington Management Group Llp6,931,7704.99%$590.52M−1,077,7190.10%
Vanguard Portfolio Management LLC6,711,7994.83%$571.78M+868,0170.03%
State Street Corp6,494,2334.67%$553.24M+749,0400.02%
Vanguard Capital Management LLC6,117,5154.40%$521.15M+628,8810.01%
FMR LLC5,031,7823.62%$428.66M−5,691,3580.02%
Avoro Capital Advisors LLC4,999,9993.60%$425.95M+1,666,6663.82%
Bank Of America Corp /De/4,635,7093.33%$394.92M+1,510,2730.03%
Geode Capital Management, LLC3,712,5012.67%$316.33M+497,0860.02%
Rtw Investments, LP2,862,0032.06%$243.81M+140,8452.08%
Polar Capital Holdings Plc2,253,6491.62%$191.99M+592,4010.45%
Price T Rowe Associates Inc /Md/1,958,9461.41%$166.88M+374,6250.02%
Goldman Sachs Group Inc1,761,5881.27%$150.07M−444,1700.01%
Capital Research Global Investors1,686,6251.21%$143.68M+915,6260.02%
Northern Trust Corp1,647,3451.18%$140.34M+205,7110.02%
William Blair Investment Management, LLC1,603,4421.15%$136.60M+515,8510.41%
Integral Health Asset Management, LLC1,600,0001.15%$136.30M–5.38%
JPMorgan Chase & Co1,588,8951.14%$139.15M+685,0900.01%
Point72 Asset Management, L.P.1,587,7121.14%$135.26M+961,6100.15%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026482160M100.0%95 / 235103 / 4732M17M
Q1 2026440146M100.0%80 / 176134 / 6432M22M
Q4 2025431149M100.0%106 / 145132 / 4720M14M
Q3 2025380142M100.0%101 / 126103 / 2617M12M
Q2 2025311138M99.1%28 / 144103 / 7119M18M
Q1 2025355136M98.1%56 / 141109 / 4414M9M
Q4 2024346131M94.5%48 / 118136 / 4712M18M
Q3 2024348138M99.0%47 / 14497 / 4127M12M
Q2 2024344137M98.3%43 / 15693 / 8531M15M
Q1 2024389121M86.7%104 / 127121 / 6133M30M
Q4 2023347119M85.5%122 / 76107 / 2323M14M
Q3 2023250110M79.1%26 / 9578 / 279M7M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

517 funds held CYTK in Q2 2026, 40% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of CYTKValue% of fundAs of
T. Rowe Price Capital Appreciation Fund6,285,9834.52%$535.50M0.76%Jun 30, 2026
iShares Core S&P Mid-Cap ETF4,646,3383.34%$395.82M0.32%Jun 30, 2026
Vanguard Total Stock Market Index Fund4,314,3563.10%$367.54M0.02%Jun 30, 2026
iShares Russell 2000 ETF3,394,9822.44%$289.22M0.35%Jun 30, 2026
Vanguard Health Care Fund3,341,2622.40%$257.71M0.68%Jul 31, 2026
Vanguard Small-Cap Index Fund3,114,8022.24%$265.35M0.14%Jun 30, 2026
SMALLCAP World Fund Inc2,997,0512.16%$255.32M0.27%Jun 30, 2026
Fidelity OTC Portfolio2,269,7001.63%$175.06M0.41%Jul 31, 2026
T. Rowe Price Mid-Cap Growth Fund, Inc.1,972,2091.42%$168.01M0.73%Jun 30, 2026
Vanguard Small-Cap Growth Index Fund1,793,3181.29%$152.77M0.32%Jun 30, 2026
Vanguard Extended Market Index Fund1,557,3171.12%$132.67M0.14%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1,484,4661.07%$126.46M1.18%Jun 30, 2026
JNL/T. Rowe Price Capital Appreciation Fund1,446,0591.04%$123.19M0.81%Jun 30, 2026
Fidelity Small Cap Index Fund1,444,6201.04%$111.42M0.33%Jul 31, 2026
T. Rowe Price Capital Appreciation Equity ETF1,160,8880.84%$98.90M1.34%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Robert I. BlumPresident & CEO, Director282,7100.20%Nov 2, 2026
Fady Ibraham MalikEVP Research & Development153,9020.11%Nov 3, 2026
Andrew CallosEVP, Chief Commercial Officer58,5550.04%Aug 31, 2026
Sung LeeEVP, Chief Financial Officer63,2210.05%Jul 2, 2026
Jeffrey HessekielChief Legal & Admin Officer107,9430.08%Mar 17, 2026
Robert WongVP, Chief Accounting Officer17,8890.01%Dec 5, 2024
B. Lynne ParshallDirector5,7840.00%Nov 12, 2026
Robert Arthur HarringtonDirector22,1270.02%Oct 20, 2026
James M. DalyDirector3,5850.00%Oct 20, 2026
Edward M. Kaye MDDirector10,6290.01%Oct 20, 2026
Nancy WysenskiDirector34,0890.02%Oct 20, 2026
John T. HendersonDirector78,7950.06%Oct 20, 2026
Wendell WierengaDirector35,6600.03%Oct 20, 2026
Robert E. LandryDirector8,1840.01%Sep 15, 2026
Muna BhanjiDirector26,3610.02%May 27, 2026
Wendall WierengaDirector32,3450.02%Jul 16, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
B. Lynne Parshall
Director
Nov 9, 2026Sale(10b5-1 plan)−2,555$55.26$141.19K5,784
B. Lynne Parshall
Director
Nov 9, 2026Sale(10b5-1 plan)−2,445$54.17$132.45K8,339
Fady Ibraham Malik
EVP Research & Development
Nov 3, 2026Sale(10b5-1 plan)−3,500$62.93$220.26K153,902
Fady Ibraham Malik
EVP Research & Development
Nov 3, 2026Option exercise+3,500$7.80$27.30K157,402
Robert I. Blum
President & CEO, Director
Nov 2, 2026Sale(10b5-1 plan)−7,500$62.81$471.08K278,544
Robert I. Blum
President & CEO, Director
Nov 2, 2026Option exercise+7,500$10.60$79.50K286,044
Fady Ibraham Malik
EVP Research & Development
Oct 20, 2026Sale(10b5-1 plan)−3,500$64.01$224.04K153,902
Fady Ibraham Malik
EVP Research & Development
Oct 20, 2026Option exercise+3,500$7.80$27.30K157,402
Nancy Wysenski
Director
Oct 16, 2026Award+97$63.92$6.20K34,089
Edward M. Kaye MD
Director
Oct 16, 2026Award+195$63.92$12.46K10,629
Robert Arthur Harrington
Director
Oct 16, 2026Award+195$63.92$12.46K22,127
James M. Daly
Director
Oct 16, 2026Award+195$63.92$12.46K3,585
Wendell Wierenga
Director
Oct 16, 2026Award+97$63.92$6.20K35,660
John T. Henderson
Director
Oct 16, 2026Award+352$63.92$22.50K78,712
Robert I. Blum
President & CEO, Director
Oct 12, 2026Sale(10b5-1 plan)−7,500$62.88$471.60K278,544
Robert I. Blum
President & CEO, Director
Oct 12, 2026Option exercise+7,500$10.60$79.50K286,044
Fady Ibraham Malik
EVP Research & Development
Oct 6, 2026Sale(10b5-1 plan)−3,500$61.38$214.83K153,902
Fady Ibraham Malik
EVP Research & Development
Oct 6, 2026Option exercise+3,500$7.80$27.30K157,402
Robert I. Blum
President & CEO, Director
Sep 28, 2026Sale(10b5-1 plan)−7,500$65.46$490.95K278,544
Robert I. Blum
President & CEO, Director
Sep 28, 2026Option exercise+7,500$10.60$79.50K286,044
Fady Ibraham Malik
EVP Research & Development
Sep 22, 2026Sale(10b5-1 plan)−3,500$68.29$239.02K153,902
Fady Ibraham Malik
EVP Research & Development
Sep 22, 2026Option exercise+3,500$7.80$27.30K157,402
Robert E. Landry
Director
Sep 15, 2026Sale(10b5-1 plan)−1,000$72.13$72.13K8,184
Robert I. Blum
President & CEO, Director
Sep 15, 2026Sale(10b5-1 plan)−97,926$69.33$6.79M0
Robert I. Blum
President & CEO, Director
Sep 14, 2026Gift+97,926––97,926
Robert I. Blum
President & CEO, Director
Sep 14, 2026Gift−97,926––278,544
Robert I. Blum
President & CEO, Director
Sep 14, 2026Gift−1,350––376,470
Robert I. Blum
President & CEO, Director
Sep 14, 2026Sale(10b5-1 plan)−7,500$73.44$550.80K377,820
Robert I. Blum
President & CEO, Director
Sep 14, 2026Option exercise+7,500$10.60$79.50K385,320
Robert E. Landry
Director
Sep 11, 2026Sale(10b5-1 plan)−1,000$74.66$74.66K9,184
Fady Ibraham Malik
EVP Research & Development
Sep 8, 2026Sale(10b5-1 plan)−3,500$75.46$264.11K153,902
Fady Ibraham Malik
EVP Research & Development
Sep 8, 2026Option exercise+3,500$7.80$27.30K157,402
B. Lynne Parshall
Director
Sep 1, 2026Sale(10b5-1 plan)−5,000$71.48$357.40K10,784
Robert I. Blum
President & CEO, Director
Aug 31, 2026Option exercise+7,500$10.60$79.50K385,320
Robert I. Blum
President & CEO, Director
Aug 31, 2026Sale(10b5-1 plan)−7,500$70.24$526.80K377,820
Andrew Callos
EVP, Chief Commercial Officer
Aug 31, 2026Sale(10b5-1 plan)−10,000$70.24$702.40K58,555
Andrew Callos
EVP, Chief Commercial Officer
Aug 31, 2026Option exercise+10,000$23.26$232.60K68,555
Fady Ibraham Malik
EVP Research & Development
Aug 18, 2026Sale(10b5-1 plan)−3,500$75.82$265.37K153,902
Fady Ibraham Malik
EVP Research & Development
Aug 18, 2026Option exercise+3,500$7.80$27.30K157,402
Robert I. Blum
President & CEO, Director
Aug 10, 2026Sale(10b5-1 plan)−7,500$76.76$575.70K377,820
Robert I. Blum
President & CEO, Director
Aug 10, 2026Option exercise+7,500$10.60$79.50K385,320
Andrew Callos
EVP, Chief Commercial Officer
Jul 30, 2026Sale(10b5-1 plan)−14,000$79.88$1.12M58,555
Andrew Callos
EVP, Chief Commercial Officer
Jul 30, 2026Option exercise+14,000$23.26$325.64K72,555
Robert I. Blum
President & CEO, Director
Jul 27, 2026Sale(10b5-1 plan)−7,500$80.87$606.53K377,820
Robert I. Blum
President & CEO, Director
Jul 27, 2026Option exercise+7,500$10.60$79.50K385,320
Fady Ibraham Malik
EVP Research & Development
Jul 21, 2026Sale(10b5-1 plan)−3,500$80.59$282.07K153,902
Fady Ibraham Malik
EVP Research & Development
Jul 21, 2026Option exercise+3,500$7.80$27.30K157,402
Edward M. Kaye MD
Director
Jul 15, 2026Award+151$82.62$12.48K10,434
James M. Daly
Director
Jul 15, 2026Award+151$82.62$12.48K3,390
Robert Arthur Harrington
Director
Jul 15, 2026Award+151$82.62$12.48K21,932
Wendell Wierenga
Director
Jul 15, 2026Award+75$82.62$6.20K35,563
Nancy Wysenski
Director
Jul 15, 2026Award+75$82.62$6.20K33,992
John T. Henderson
Director
Jul 15, 2026Award+272$82.62$22.47K78,360
Robert I. Blum
President & CEO, Director
Jul 13, 2026Option exercise+7,490$10.60$79.39K385,310
Robert I. Blum
President & CEO, Director
Jul 13, 2026Sale(10b5-1 plan)−7,490$82.02$614.33K377,820
Robert I. Blum
President & CEO, Director
Jul 13, 2026Sale(10b5-1 plan)−10$82.02$820377,820
Fady Ibraham Malik
EVP Research & Development
Jul 7, 2026Option exercise+3,500$7.80$27.30K157,402
Fady Ibraham Malik
EVP Research & Development
Jul 7, 2026Sale(10b5-1 plan)−3,500$86.62$303.17K153,902
Robert I. Blum
President & CEO, Director
Jul 1, 2026Sale(10b5-1 plan)−7,500$84.92$636.90K377,830
Sung Lee
EVP, Chief Financial Officer
Jul 1, 2026Sale(10b5-1 plan)−1,112$87.79$97.62K63,221

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
12.98%
18M shares short
Days to cover
14.2
At 1M shares a day
Change since last report
-3.7%
From 19M shares
Short volume, 20 days
53.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cytokinetics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 98,000 shares on Sep 14, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
B. Lynne Parshall
Director
Nov 9, 20265,000$268.45KNov 9, 2026Restricted Stock Units
Fady Ibraham Malik
Officer
Oct 20, 202616,386$1.03MOct 20, 2026Exercise of Stock Options
Robert I. Blum
Director, Officer
Oct 13, 202622,500$1.42MOct 12, 2026Exercise of Stock Options
Robert I. Blum
President, CEO, Director
Sep 15, 202697,926$7.09MSep 15, 2026Transfer
Robert E. Landry
Director
Sep 11, 20262,000$147.24KSep 11, 2026Restricted Stock Units
B. Lynne Parshall
Director
Sep 1, 20265,000$354.55KSep 1, 2026Restricted Stock Units
Andrew Callos
Officer
Jul 30, 202624,000$1.88MJul 30, 2026Exercise of Stock Options
Fady Ibraham Malik
Officer
Jul 7, 202624,500$2.10MJul 7, 2026Exercise of Stock Options
Robert I. Blum
Director, Officer
Jul 1, 202652,500$4.47MJul 1, 2026Exercise of Stock Options
Sung Lee
Officer
Jun 29, 20269,503$781.05KJun 29, 2026Exercise of Stock Options
Sung Lee
Officer
Jun 26, 20266,695$540.96KJun 26, 2026Restricted Stock Units
Sung Lee
Officer
Jun 24, 202638,730$3.10MJun 24, 2026Exercise of Stock Options
Edward M. Kaye MD
Director
Jun 1, 20262,933$225.14KJun 1, 2026Restricted Stock Units
Wendell Wierenga
Director
May 5, 20264,032$266.31KMay 5, 2026Exercise of Stock Options
John T. Henderson
Director
May 5, 202620,000$1.32MMay 5, 2026Exercise of Stock Options

Congress trades

5 trades in Cytokinetics reported by 2 members of the House

MemberTypeTradedAmountFiled
Gilbert Cisneros
CA31
BoughtSep 29, 2026$1K–15KOct 12, 2026
Gilbert Cisneros
CA31
BoughtJun 30, 2026$1K–15KJul 2, 2026
Gilbert Cisneros
CA31
BoughtOct 9, 2025$1K–15KNov 18, 2025
Lisa McClain
MI09 · spouse
SoldJun 17, 2025$1K–15KAug 13, 2025
57 days late
Lisa McClain
MI09 · spouse
BoughtJun 11, 2025$1K–15KAug 13, 2025
63 days late

See a number that looks wrong?